Ramucirumab and Paclitaxel in Patients with Gastric Cancer and Prior Trastuzumab: Subgroup Analysis from RAINBOW Study
-
- Ferdinando De Vita
- Division of Medical Oncology, Department of Precision Medicine, University of Campania ‘Luigi Vanvitelli’, Naples, 80138, Italy
-
- Christophe Borg
- Department of Medical Oncology, University Hospital of Besançon, Besançon, 25000, France
-
- Gabriella Farina
- Department of Medical Oncology, Fatebenefratelli Sacco Hospital, Milan, 20121, Italy
-
- Ravit Geva
- Oncology Division, Tel Aviv University, Tel Aviv, 6997801, Israel
-
- Iris Carton
- Eli Lilly & Company, Brussels, 1000, Belgium
-
- Hera Cuku
- Eli Lilly & Company, Florence, 50019, Italy
-
- Ran Wei
- Eli Lilly & Company, Indianapolis, IN 46285, USA
-
- Kei Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan
この論文をさがす
説明
Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy. Patients & methods: Of adult patients enrolled in the RAINBOW study, 39 had received prior trastuzumab therapy. Of these, 20 patients were treated with ramucirumab plus paclitaxel and 19 patients with placebo plus paclitaxel within the RAINBOW trial. Results: Overall survival was longer with ramucirumab plus paclitaxel (11.4 months; 95% CI: 7.0-17.9) versus placebo plus paclitaxel (7.0 months; 95% CI: 3.4-14.6), hazard ratio: 0.68 (0.33-1.41); p = 0.30. Longer progression-free survival, higher objective response were observed in ramucirumab combination group. Conclusion: Ramucirumab plus paclitaxel demonstrated efficacy benefits with manageable safety profile in a subgroup of patients pretreated with trastuzumab. Clinical trial registration number: NCT01170663.
収録刊行物
-
- Future Oncology
-
Future Oncology 15 (23), 2723-2731, 2019-06-25
Informa UK Limited
- Tweet
キーワード
- Male
- Esophageal Neoplasms
- Paclitaxel
- Antineoplastic Agents
- Adenocarcinoma
- Middle Aged
- Trastuzumab
- Antibodies, Monoclonal, Humanized
- Progression-Free Survival
- Ramucirumab
- gastric cancer; HER-2 inhibitor; prior trastuzumab; ramucirumab plus paclitaxel; targeted therapy; VEGFR-2 inhibitor; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Stomach Neoplasms; Trastuzumab
- Stomach Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Humans
- Female
- Esophagogastric Junction
詳細情報 詳細情報について
-
- CRID
- 1360580240165697280
-
- ISSN
- 17448301
- 14796694
-
- HANDLE
- 11591/423433
-
- PubMed
- 34269069
-
- データソース種別
-
- Crossref
- OpenAIRE